



Epidemiological Studies of HPV Infection and Vaccination

Guest Editor:

Dr. Masayuki Sekine

Department of Obstetrics and
Gynecology, Niigata University
Graduate School of Medical and
Dental Sciences, Niigata, Japan

Deadline for manuscript
submissions:

closed (10 September 2021)

Message from the Guest Editor

The effectiveness of the HPV vaccine for precancerous lesions of cervical cancer has been demonstrated in many epidemiological studies, and the effect on cervical invasive cancer was also reported for the first time in the world from Sweden last October. It has been reported that persistent HPV infection increases the carcinogenic risk of vaginal/vulvar cancer, penile cancer, anal cancer, and oropharyngeal cancer; however, there are still few reports on the course of HPV infection and the efficacy of HPV vaccines at those sites. In addition, the epidemiologic *profiles* of *type-specific HPV infection* vary from region to region, and their epidemiological data are very important in predicting the efficacy of 9-valent vaccines. The understanding the profile of HPV infection will help develop new cancer screening methods. In this Special Issue, we will focus on HPV infection not only in the cervix but also in other parts of the body, and would like to provide a deeper discussion on the effectiveness of HPV vaccine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com